In the Claims

1-58 (canceled).

59 (Previously presented). A method of treating a disorder selected from the group consisting of a metabolic disorder, a gynecologic disorder, a chronic inflammatory disorder and a liver or renal disorder comprising the administration of a composition comprising a modulator of a T-cadherin polypeptide to an individual having said disorder.

60 (Previously presented). The method of claim 59, wherein said disorder is a metabolic disorder selected from the group consisting of obesity, type II diabetes, insulin resistance, hypercholesterolemia, hyperlipidemia, dyslipidemia, syndrome X, anorexia and cachexia.

61 (Previously presented). The method of claim 60, wherein said modulator is used in combination with a known drug for the treatment of said disorder.

62 (Previously presented). The method of claim 59, wherein said modulator is an agonist.

63 (Previously presented). The method of claim 60, wherein said disorder is a metabolic disorder selected from the group consisting of anorexia and cachexia.

64 (Previously presented). The method of claim 61, wherein said disorder is a metabolic disorder selected from the group consisting of anorexia and cachexia.

65 (Previously presented). The method of claim 64, wherein said modulator is an antagonist.

66 (New). The method of claim 59, wherein said modulator is soluble T-cadherin.

67 (New). The method of claim 66, wherein said soluble T-cadherin consists of amino acids 23 to 692 of SEQ ID NO: 1.

68 (New). The method of claim 66, wherein said soluble T-cadherin comprises SEQ ID NO: 1, wherein the GPI-anchor site has been mutated.

69 (New). The method of claim 66, wherein said soluble T-cadherin comprises a heterologous sequence fused to a polypeptide that consists of amino acids 23 to 692 of SEQ ID NO: 1.

70 (New). The method of claim 66, wherein said soluble T-cadherin a polypeptide that comprises SEQ ID NO: 1, wherein the GPI-anchor site has been mutated.